                               SEQUENCE LISTING

<110> RA PHARMACEUTICALS, INC.
 
<120> MODULATORS OF COMPLEMENT ACTIVITY

<130> 2011.1022PCT

<140> PCT/USxx/xxxxx
<141> 2017-12-XX

<150> 62/555,711
<151> 2017-09-08

<150> 62/525,284
<151> 2017-06-27

<150> 62/491,702
<151> 2017-04-28

<150> 62/430,959
<151> 2016-12-07

<160> 1     

<170> PatentIn version 3.5

<210> 1
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<223> N-term Ac

<220>
<221> MISC_FEATURE
<222> (1)..(6)
<223> /note="Lactam bridge between residues"

<220>
<221> MOD_RES
<222> (7)..(7)
<223> N-methyl-aspartic acid 

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Tert-butylglycine 

<220>
<221> MOD_RES
<222> (10)..(10)
<223> 7-azatryptophan 

<220>
<221> MOD_RES
<222> (14)..(14)
<223> Cyclohexylglycine 

<220>
<221> MOD_RES
<222> (15)..(15)
<223> N-epsilon-(PEG24-gamma-glutamic acid-N-alpha-
      hexadecanoyl)Lys

<400> 1
Lys Val Glu Arg Phe Asp Xaa Xaa Tyr Xaa Glu Tyr Pro Xaa Lys 
1               5                   10                  15  

